Purpose: To evaluate and compare the visual acuity outcomes and optical performances of eyes implanted with two diffractive multifocal intraocular lens (IOL) models with either a plate haptic design or a modified-C design. between June 2012 and May 2013. The 6 month postoperative visual acuity, refraction, defocus curve, contrast sensitivity, and wave-front aberration were evaluated and compared between these eyes, using different IOL models. Results: One hundred fifty-eight eyes of 107 patients were included in this study. Significant improvement in visual acuities and refraction was found in both groups after cataract surgery (P0.01). The visual acuity and contrast sensitivity were statistically better in group 1 than in group 2 (P0.01). No statistically significant difference in the corneal higher-order aberrations was found between the two groups (P0.05). However, the ocular higher-order aberrations in group 2 were significantly greater than in group 1 (P0.05). Conclusion: At 6 months postoperatively, both Acriva UD Reviol BB MFM 611 IOL and Acriva UD Reviol BB MF 613 IOL achieved excellent visual and refractive outcomes. The multifocal IOL model with plate haptic design resulted in better optical performances than that with the modified-C haptic design.
Introduction
Multifocal intraocular lens (IOL) implantation, introduced more than 20 years ago, is a popular procedure that achieves good visual acuity for both distance and near vision. 1, 2 Generally speaking, there are 3 types of multifocal IOLs: refractive, diffractive, and a combination of diffractive and refractive. 3, 4 Multifocal IOLs with a diffractive optic design have been proven to provide a significantly better near vision and reading performance than refractive multifocal IOLs and monofocal IOLs. 5 With the addition of a +3.75 D near power, good intermediate distance visions from diffractive multifocal IOL models were also proven in previous studies. 6, 7 In this study, the visual and optical performances were evaluated and compared between two new-generation multifocal IOL models, both with a near addition power of +3.75 D but with different haptic designs.
This retrospective, single-center study comprised cataract patients who underwent cataract surgery with diffractive multifocal IOL implantation from June 2012 to May 2013 at the Shinagawa LASIK Center, Tokyo, Japan. The inclusion criteria were patients with incipient or moderate cataracts resulting in a significant reduction of the visual quality. The exclusion criteria were patients with active ocular diseases or significant amounts of corneal aberrations observed on the topography map. Eyes with serious postoperative complications (such as posterior-capsular opacity [PCO] and obvious capsule contraction) were likewise excluded to achieve the accurate outcomes of visual and optical performance. These included eyes were randomly divided into two groups and implanted with multifocal IOLs: Acriva UD Reviol BB MFM 611 (VSY Biotechnology, Amsterdam, the Netherlands) for group 1 and Acriva UD Reviol BB MF 613 (VSY Biotechnology, Amsterdam, the Netherlands) for group 2. All patients read and signed the informed consent forms, which explained the surgical procedure, possible risks, and patient rights. The study was carried out with approval from the Institutional Review Board (Matsumoto Clinic, Tokyo, Japan), and all patients consented.
Preoperative examinations
Preoperative examinations included uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), manifest refraction spherical equivalent (MRSE), uncorrected near visual acuity (UNVA), corrected near visual acuity (CNVA), slit lamp biomicroscopy, funduscopy, intraocular pressure (Computerized Tonometer TM ; Topcon Corp, Tokyo, Japan), tomography (Pentacam TM ; Oculus Optikgeräte GmbH, Wetzlar, Germany), and corneal endothelial cell count (Noncon Robo TM FA3609; Konan Medical Inc, Hyogo, Japan). 8 IOLMaster TM (Carl Zeiss Meditec, Jena, Germany) was used for the biometry and power calculation of the multifocal IOLs. The visual and refractive outcomes of all patients were measured by an independent optometrist. All examiners were masked to the IOL models implanted into these patients.
Multifocal iOls
The diffractive multifocal IOL with a plate haptic design used in this study was the Acriva UD Reviol BB MFM 611 IOL ( Figure 1, left) . According to the manufacturer, this diffractive multifocal IOL has 3.75 D of addition power and ultradefinition aspheric optic design. It can provide high-quality far, middle, and near vision. It has been verified to have smooth ridges at the diffractive ring transitions to increase retinal image quality. It also has a 360 degree continuous square optic and haptic edge to reduce the PCO formation. 6 The Acriva
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Reviol BB MF 613 IOL has the same ultradefinition aspheric optic design as the Acriva UD Reviol BB MFM 611 IOL, but with a modified-C haptic design (Figure 1, right) . The C haptic size is 13.00 mm, with a 0° haptic angle. Both multifocal IOL models are made of hydrophilic acrylic with a hydrophobic surface. Sixty percent of the intraocular light was allotted for far focus, and 40% for near.
surgical technique
All surgeries were performed by the same surgeon (MT), using femtosecond laser-assisted phacoemulsification. 9 After topical anesthesia and adequate dilation, femtosecond laser ( Catalys TM Precision Laser System; Optimedica Corp, Sunnyvale, CA, USA) was used for the continuous curvilinear capsulorrhexis (CCC) and lens fragmentation of all cataracts. The incision was created on the steepest corneal meridian. 
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Multifocal intraocular lenses with a plate haptic or a modified-C haptic Viscoelastic material (Provisc TM ; Alcon Corp, Fort Worth, TX, USA) was injected, and the cut capsule was removed. Phacoemulsification was performed using the Infiniti® Vision System (Alcon Corp). The foldable multifocal IOL was inserted and rotated into the intact capsular bag. The viscoelastic material was completely removed by irrigation and aspiration. All incisions were left sutureless.
Postoperative treatments
In all cases, the postoperative medications were given as follows: a 500 mg oral levofloxacin (Cravit TM ; Daiichi Sankyo, Tokyo, Japan) once a day for 3 days and 0.1% diclofenac sodium eye drops (Diclofenac Ophthalmic Solution 0.1%; Nitto Medic, Toyama, Japan), 0.1% dexamethasone metasulfobenzoate sodium (D·E·X TM ; Nitto Medic), and 0.5% moxifloxacin hydrochloride (Vegamox TM ; Alcon Corp) five times a day for 1 week. After 1 week, diclofenac use was reduced to 4 times a day for 1 month, and the latter drugs were shifted to topical 0.1% fluorometholone ophthalmic suspension (Fluorometholone Ophthalmic Suspension 0.1% T; Nitto Medic) and 0.3% ofloxin ophthalmic solution (Ofloxin Ophthalmic Solution 0.3%; Nitto Medic), prescribed four times a day up to 1 month, after which their use was discontinued.
Postoperative examinations
Postoperatively, visual and refractive examinations were routinely performed during the 6 month follow-up, following the same investigational protocol. At 6 months postoperatively, a defocus curve was obtained by spectacle defocus from +2.00 D to −5.00 D in 0.50 D steps from the patient's manifest refraction. The direct comparison method was used to compare the visual acuities between two groups at each defocus level. 10 Functional acuity contrast was tested using the Takagi TM Contrast Glare Tester CGT-1000 (Takagi Seiko Co Ltd, Nagano-Ken, Japan) for different ambient light conditions (with and without glare) at luminance levels of 21 candelas (cd)/m 2 (day testing) and 11 cd/m 2 (night testing). 11 Wave-front aberration was tested using the Wave-Front Analyzer TM KR-1W (Topcon Corp) 6 months postoperatively.
statistical analysis
Statistical analysis was performed with JMP TM 9 statistical package (SAS Institute, Inc, Cary, NC, USA) software. Descriptive statistical results were presented as mean and standard deviation. To compare the differences between the two groups, one-way analysis of variance and KruskalWallis tests were used for parametric and nonparametric tests, respectively. Results with P0.05 were considered statistically significant.
Results
A total of 158 eyes of 107 patients were incl uded in this study. Table 1 shows the preoperative and 6 month postoperative outcomes in visual and refractive parameters of the two groups. No statistically significant differences in terms of age, visual acuity, and refractive parameters were found between the two groups preoperatively (P0.05). At 6 months postoperatively, significant improvements in UDVA, CDVA, MRSE, UNVA, and CNVA were found in both groups (P0.05). Comparing the two groups, plate haptic multifocal IOLs (group 1) provided statistically better outcomes in UDVA, CDVA, and CNVA (P0.05). Figure 2 summarizes the cumulative percentage of the UDVA in each group 6 months postoperatively. Figure 3 shows the cumulative percentage of the UNVA. Eighty-five percent of the eyes in group 1 and 74% of the eyes in group 2 achieved a UDVA of 20/20 (0.00 logMAR) or better. For UNVA, 69% of the eyes in group 1 and 54% of the eyes in group 2 achieved Jaeger 3 (0.18 logMAR) or better at the end of the follow-up. Figure 4 shows the contrast sensitivities of two groups 6 months postoperatively. At any level of the target size (visual angle, degree [d] ), the mean values of contrast sensitivity were higher in group 1 than in group 2. These differences between the two groups were statistically significant both under photopic (6. Reviol BB MFM 611 IOL and −0.06±0.09 logMAR for the Acriva UD Reviol BB MF 613 IOL; both peaks were present at 33 cm (−3.00 D). Table 2 summarizes the comparison of postoperative higher-order aberrations (HOAs) in the two groups. No statistically significant difference in corneal HOAs for either photopic vision (4 mm diameter) or scotopic vision (6 mm diameter) was found between two groups at the end of the follow-up (P0.05). However, the ocular HOAs in group 2 were significantly greater than in group 1 (P0.05). Notes: Corneal and ocular wavefront aberrations were obtained using Mire ring sensor (Wave-Front analyzer Kr-1W, Topcon Corporation, Tokyo, Japan) and hartmannShack Sensor (Wave-Front Analyzer KR-1W, Topcon Corporation), respectively. S3, S4, S5 and S6 are the RMS of the third-, fourth-, fifth-and sixth-order Zernike coefficients, respectively; s3+5, total coma aberration; s4+6, total spherical aberration; Total, total higher-order aberration (s3+4+5+6). group 1, eyes with acriva UD reviol MFM 611 intraocular lens. group 2, eyes with acriva UD Reviol MF 613 intraocular lens (VSY Biotechnology, Amsterdam, the Netherlands). Statistically significant at the level *P0.05.
Discussion
IOL models with a near addition of +3.75 D and a 360 degree continuous square edge. Previous study has proven that a clear Acriva UD Reviol model with plate haptic design (Acriva UD Reviol MFM 611) provides excellent visual acuity and contrast sensitivity. 6 Theoretically, both Acriva UD Reviol BB MF 613 and BB MFM 611 should have yielded the same visual and optical performances because they have the same optic design. However, many factors can actually affect the visual and optical outcomes of multifocal IOL implantations and can cause patient dissatisfaction, such as IOL decentration or tilt. 3, 12 Haptic deformation and flexion caused by anterior capsule contraction were thought to play major roles in these decentrations and tilts. 13, 14 The aim of the present study was to evaluate and compare the visual and optical performances of these two multifocal IOL models with different haptic designs.
Before the cataract surgery, no statistically significant differences were found in age, UDVA, CDVA, MRSE, UNVA, or CNVA between the two groups. At 6 months postoperatively, significant improvements in distance (8 lines increased in both groups) and near (7 lines increased in group 1, 8 lines in group 2) visual acuities were found, which confirmed the efficacy of the two multifocal IOL models.
Nevertheless, the plate haptic IOL model (Acriva UD Reviol BB MFM 611, group 1) appeared to yield better visual and optical performances than the C haptic IOL model (Acriva UD Reviol BB MF 613, group 2). Similar outcomes can be found in eyes implanted with some other monofocal and refractive multifocal IOL models. [13] [14] [15] [16] [17] [18] For example, the plate haptic IOL models of Lentis Mplus TM (Oculentis GmbH, Berlin, Germany) can provide better refractive predictability and optical quality than the C haptic IOL models. 14 In the current study, because of the same optic design, the visual and optical differences between two diffractive multifocal IOL models might be caused by their different positional stabilities within the capsular bags. It was found that diffractive IOLs were much more sensitive to their own stability than monofocal and refractive multifocal IOLs. 13 Even a small misalignment of the central concentric rings can lead diffractive multifocal IOLs to provide significantly reduced results. In the current study, the different stabilities between the two models would have been because of the following reasons: first, the haptic designs of these models should have been the major reason for their different stabilities. It has been found that three-piece C haptic IOLs had a greater tendency toward more decentration than one-piece IOLs;
18 plate haptics provided greater stability for IOLs than the C haptics and cannot be easily affected by the IOL orientation. 13, 18, 19 It was also proven that the IOL tilt and decentration were correlated with coma and total aberrations. 20 Because our outcomes include both visual and optical performances, those eyes that could affect the visual and optical measurements (such as PCO and other serious postoperative complications) were excluded from both groups. This makes the IOL decentration measurements unfeasible for statistically analyzing the stability performance of these IOLs. Even so, the visual and optical differences between two groups have indirectly reflected that a plate haptic design could provide multifocal IOL models better stabilities.
Second, the material and biocompatibility of IOLs have also played important roles in IOL stability. For example, capsule contraction syndrome (including anterior capsule opacification and capsulorrhexis shrinkage) was found in 
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Multifocal intraocular lenses with a plate haptic or a modified-C haptic the eyes with silicone IOLs. 21, 22 In addition, hydrophilic multifocal IOLs were thought to be more sensitive to postoperative decentration. 13 In this study, both multifocal IOL models are produced from an ultrapure acrylate monomer that has a water content of 25%. Although this material makes IOLs much elastic and malleable, it could also render IOLs "soft" haptics. Thus, the modified C haptic of the Acriva UD Reviol BB MF 613 would be a little "weak" to stabilize the IOL in some patients who have strong capsule contraction syndrome.
In addition, a "perfect" CCC can give IOLs 360 degree support and excellent IOL fixation. 23 Compared with a manual CCC, the femtosecond laser can produce a sharp and clean-edged capsulotomy without radial nicks and tears. [24] [25] [26] Meanwhile, a properly sized, shaped, and centered CCC can be precisely created by a femtosecond laser for the "ideal" IOL position. [27] [28] [29] In the present study, a new femtosecond laser device (Catalys TM Precision Laser System) was used on all our cataract patients for the CCC incisions. No serious intraoperative complication (such as radial nicks and tears) occurred during these surgeries.
Conclusion
In summary, both multifocal IOL models provided excellent outcomes in distance and near visual acuities and refraction during our 6 month follow-up. Compared with the Acriva UD Reviol BB MF 613 IOL model, the Acriva UD Reviol BB MFM 611 IOL model has a same optic design but appeared to result in better optical performance. The plate haptic design seems to support a better stability for the diffractive multifocal IOL than the C haptic design. Further studies should be performed to compare their longer-term visual and optic outcomes with other plate or C haptic multifocal IOL models.
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